Co-founder and CEO of German biotechnology company BioNTech Ugur Sahin arrives to attend the Vaccine Equity for Africa event in Berlin on August 27, 2021. Sahin told the public to get a third dose of the Pfizer-BioNTech BNT162b messenger RNA gene therapy vaccine now to protect against Omicron while they wait for the March of 2022 rollout of a three-dose Omicron-specific course. (Image: TOBIAS SCHWARZ/AFP via Getty Images)

Supporters of mandatory vaccination and vaccine passports may have a tough decision lying ahead for them after BioNTech, the company partnered with Pfizer on one of the two main novel gene therapy messenger RNA injections globally distributed, said a booster shot is needed now to protect against the Omicron variant in addition to a three dose Omicron-specific vaccine set to be deployed in March.

The comments were made by CEO Ugur Sahin during a Dec. 8 press conference held by BioNTech and Pfizer after the partners issued a same day press release that stated internal studies showed a booster of the existing BNT162b mRNA injection provides “more than a 25-fold reduction in neutralization titers” against Omicron.

The release came just one day following a study published by South African researchers funded by the Bill and Melinda Gates Foundation and the U.S. National Institutes of Health which found that Omicron evades Pfizer vaccine-generated antibodies by a factor of 41 unless the patient also has natural immunity derived from a previous infection.

Source:  https://www.visiontimes.com/2021/12/09/booster-now-three-dose-omicron-vaccine-in-march-biontech-ceo.html